Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data
- Northwestern University, United States
Figures
Figure 1 with 1 supplement
Tumor xenograft experiment testing efficacy of cimetidine in inhibiting the growth of tumors in SCID mice.
Female SCID mice bearing subcutaneous A549 human lung adenocarcinomas (A) or ACHN renal cell carcinomas (B) were randomized into three treatment groups once tumors reached a calculated volume of 100 mm3. Mice were intraperitoneally injected with 100 mg/kg cimetidine, vehicle (PBS), or 2 mg/kg doxorubicin. Tumor volumes were measured by caliper for the duration of the study. For each condition tumor volume was normalized relative to the average Day 1 values. Means reported and error bars represent s.e.m. Number of mice: (A) A549 tumors: n=14 (vehicle), n=13 (cimetidine), n=4 (doxorubicin) (B) ACHN tumors: n=15 (vehicle), n=15 (cimetidine). Two-tailed Welch’s t-test on Day 11 relative volumes between vehicle or doxorubicin treated A549 tumors; t(6.73) = 2.68, uncorrected p=0.0325 with a priori alpha level = 0.0167; (Bonferroni corrected p=0.0976). Two-way ANOVA interaction between cell line (A549 or ACHN) and treatment (vehicle or cimetidine) on natural log transformed Day 11 relative volumes; F(1,53) = 3.88, p=0.054. Pairwise contrast between A549 tumors treated with vehicle or cimetidine; t(53) = 2.16, uncorrected p=0.035 with a priori alpha level = 0.0167; (Bonferroni corrected p=0.105). Pairwise contrast between ACHN tumors treated with vehicle or cimetidine; t(53) = 0.58, uncorrected p=0.562 with a priori alpha level = 0.0167; (Bonferroni corrected p>0.99). Additional details for this experiment can be found at https://osf.io/fh6gn/.
Figure 1—figure supplement 1
Individual tumor xenografts.
This is the same experiment as in Figure 1, but with the data plotted for each animal rather than averages. Female SCID mice bearing subcutaneous A549 human lung adenocarcinomas (A) or ACHN renal cell carcinomas (B) were intraperitoneally injected with 100 mg/kg cimetidine, vehicle (PBS), or 2 mg/kg doxorubicin. For each condition tumor volume was normalized relative to the average Day 1 values. Number of mice: (A) A549 tumors: n=14 (vehicle), n=13 (cimetidine), n=4 (doxorubicin) (B) ACHN tumors: n=15 (vehicle), n=15 (cimetidine). Additional details for this experiment can be found at https://osf.io/fh6gn/.
Figure 2
Final tumor weights from xenograft experiment testing efficacy of cimetidine in inhibiting the growth of tumors in SCID mice.
At the end of the predefined study period (Day 12), tumors from the xenograft experiment reported in Figure 1 were excised and weighed. Box and whisker plot with median represented as the line through the box, means represented as the solid red circle, and whiskers representing values within 1.5 IQR of the first and third quartile. Number of mice: A549 tumors: n=14 (vehicle), n=13 (cimetidine), n=4 (doxorubicin). ACHN tumors: n=15 (vehicle), n=15 (cimetidine). Two-tailed Welch’s t-test between vehicle or doxorubicin treated A549 tumors; t(4.078) = 0.771, p=0.483. Two-way ANOVA interaction between cell line (A549 or ACHN) and treatment (vehicle or cimetidine); F(1,53) = 0.00005, p=0.994. Two-way ANOVA main effect of cell line (A549 or ACHN); F(1,53) = 7.56, p=0.00814. Additional details for this experiment can be found at https://osf.io/fh6gn/.
Figure 3
Meta-analyses of each effect.
Effect size (Cohen’s d) and 95% confidence interval are presented for Sirota et al., 2011, this replication attempt (RP:CB), and a meta-analysis to combine the two effects of day 11 tumor volume comparisons. Sample sizes used in Sirota et al., 2011 and this replication attempt are reported under the study name. Random effects meta-analysis of A549-derived tumors treated with vehicle (PBS) compared to 100 mg/kg cimetidine (meta-analysis p=0.0043), ACHN-derived tumors treated with vehicle (PBS) compared to 100 mg/kg cimetidine (meta-analysis p=0.917), and A549-derived tumors treated with vehicle (PBS) compared to 2 mg/kg doxorubicin (meta-analysis p=0.021). Additional details for these meta-analyses can be found at https://osf.io/jcghv/.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data
eLife 6:e17044.
https://doi.org/10.7554/eLife.17044
